Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Clonal Hematopoiesis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PPM1D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPM1D Wild-Type / Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PPM1D Products |
| Gene Delivery | PPM1D Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PPM1D Products |
| Benchmark Ab | Anti-PPM1D Recombinant Positive Control Recombinant positive control antibody. |
View PPM1D Products |
| Validator | PPM1D siRNA Set For knockdown verification. |
View PPM1D Products |
| Related Target A | TP53 PPM1D directly dephosphorylates and inactivates the p53 tumor suppressor. |
View TP53 Products |
| Related Target B | MAPK14 p38 MAPK is a key downstream substrate of PPM1D involved in stress response. |
View MAPK14 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Screening for allosteric inhibitors | Full-length PPM1D recombinant proteins strictly verified by mass spectrometry |
| Targeting truncation mutants (CHIP-associated) | Specific PPM1D truncation mutant proteins available with >95% purity |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PPM1D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PPM1D therapeutics is intensifying, with major players shifting focus from traditional oncology indications to clonal hematopoiesis of indeterminate potential (CHIP) and associated cardiovascular risks. As first-generation allosteric inhibitors reach preclinical validation, the next wave of R&D is targeting PPM1D truncation mutations that escape proteasomal degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Preclinical Biotechs, Academic Consortia | Breast Cancer, Ovarian Cancer | Phosphatase Activity Assay (Need high-purity WT protein) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Hematological Malignancies, CHIP | Degradation Validation (Need Lentivirus for stable cell lines) |
| Combination Therapies | Translational Oncology Labs | p53-Wildtype Refractory Tumors | Selectivity Assay (Need Mutant vs WT Recombinant Proteins) |